Education
University of Birmingham. University of Toronto.
assistant founder medical scientist chief
University of Birmingham. University of Toronto.
Since its inauguration in 1972, the Medal has been awarded ten times. Six recipients are Nobel Laureates. Wallace is an adjunct professor in the Faculty of Medicine at the University of Calgary, the Department of Pharmacology and Toxicology at the University of Toronto, and in the University Camilo Castelo Branco in São Paulo Paulo, Brazil.
He is Chief Scientific Officer of Antibe Therapeutics Incorporated., which he founded.
Antibe Therapeutics is based in Toronto, Canada, and trades on the Toronto Venture Exchange ( Association of Technical Employees:Turn- und Sportverein). Wallace"s current research focuses on the mechanisms of internal injury induced by non-steroidal anti-inflammatory drugs (NSAIDs) and other anti-inflammatory drugs.
In parallel, Wallace has been investigating the factors that regulate and promote healing of ulcers. He is also researching the causes of inflammatory bowel disease (Crohn"s Disease and Ulcerative Colitis).
Wallace"s career has centred on the use of gaseous mediators to treat inflammation, particularly intestinal injury and dysfunction.
Wallace has published more than 450 peer-reviewed papers and is among the top 0.5 percent of biomedical scientists worldwide in citations (>34,000), with a current Hirsch index of 103. From 1989 to 2009, Wallace was a professor of Pharmacology and Therapeutics at the University of Calgary, where he held the Canada Research Chair in Inflammation. In 2005, he acted as an invited expert for the United States Food and Drug Administration"s review of COX-2 inhibitors such as Vioxx.
Wallace graduated from Queen"s University with his Bachelor of Science and Master of Science and received his Doctor of Philosophy from the University of Toronto.
He completed his post-doctoral studies under Doctor Brendan Whittle, Sir John Vane and Sir Salvador Moncada at Wellcome Research Laboratories in the United Kingdom. From 1986 to 1989, he was an assistant professor at Queen's University. In 1989, he joined the University of Calgary, where he founded the Inflammation Research Network and held the Crohn"s and Colitis Foundation of Canada Chair in Intestinal Disease Research.
Wallace received an Master of Business Administration from the University of Birmingham (United Kingdom) in 2008. In 2014, Wallace co-founded the Inflammation Research Network of Canada.
Wallace co-founded NicOx in 1996, creating the first pharmaceutical company to commercialize gaseous mediator technology.
This board oversaw the development of nitric oxide-releasing NSAIDs. Antibe Therapeutics became a publicly traded company (Toronto Venture Exchange) in July 2013.
He is a fellow of the Royal Society of Canada, a member of the Brazilian Academy of Sciences, a fellow of the British Pharmacological Society, and a fellow and former President of the Canadian Association of Gastroenterology.